Stephens assumed coverage on shares of Cutera (NASDAQ:CUTR) in a report published on Tuesday morning, MarketBeat reports. The firm issued an overweight rating and a $60.00 target price on the medical device company’s stock.
Other equities analysts have also recently issued reports about the company. Zacks Investment Research cut Cutera from a hold rating to a sell rating in a report on Tuesday, December 26th. Gabelli reissued a buy rating on shares of Cutera in a report on Friday, February 16th. Finally, BidaskClub raised Cutera from a hold rating to a buy rating in a report on Tuesday, December 12th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of Buy and an average target price of $45.00.
Cutera (CUTR) opened at $53.30 on Tuesday. The firm has a market capitalization of $701.06, a PE ratio of 66.58, a P/E/G ratio of 1.10 and a beta of 0.51. Cutera has a 1-year low of $18.50 and a 1-year high of $54.25.
Cutera (NASDAQ:CUTR) last announced its quarterly earnings data on Wednesday, February 14th. The medical device company reported $0.42 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.33 by $0.09. The company had revenue of $47.60 million for the quarter, compared to analysts’ expectations of $43.96 million. Cutera had a return on equity of 18.31% and a net margin of 19.80%. Cutera’s revenue for the quarter was up 25.6% compared to the same quarter last year. During the same period last year, the firm posted $0.30 EPS. analysts anticipate that Cutera will post 1.1 EPS for the current year.
In other Cutera news, Director David B. Apfelberg sold 1,000 shares of Cutera stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $47.40, for a total value of $47,400.00. Following the transaction, the director now directly owns 8,259 shares of the company’s stock, valued at approximately $391,476.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider James A. Reinstein sold 7,175 shares of Cutera stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $45.35, for a total value of $325,386.25. Following the completion of the transaction, the insider now directly owns 132,284 shares in the company, valued at $5,999,079.40. The disclosure for this sale can be found here. Over the last three months, insiders have sold 14,018 shares of company stock worth $637,766. 3.30% of the stock is currently owned by insiders.
A number of institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System increased its stake in Cutera by 1.3% in the 2nd quarter. California State Teachers Retirement System now owns 23,405 shares of the medical device company’s stock worth $606,000 after purchasing an additional 300 shares during the period. Nationwide Fund Advisors increased its stake in Cutera by 8.4% in the 2nd quarter. Nationwide Fund Advisors now owns 7,216 shares of the medical device company’s stock worth $187,000 after purchasing an additional 561 shares during the period. The Manufacturers Life Insurance Company increased its stake in Cutera by 12.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,479 shares of the medical device company’s stock worth $297,000 after purchasing an additional 1,230 shares during the period. Legal & General Group Plc increased its stake in Cutera by 69.6% in the 3rd quarter. Legal & General Group Plc now owns 3,600 shares of the medical device company’s stock worth $149,000 after purchasing an additional 1,477 shares during the period. Finally, American International Group Inc. increased its stake in Cutera by 19.4% in the 4th quarter. American International Group Inc. now owns 10,589 shares of the medical device company’s stock worth $480,000 after purchasing an additional 1,724 shares during the period. 95.29% of the stock is currently owned by institutional investors and hedge funds.
WARNING: “Cutera (CUTR) Receives New Coverage from Analysts at Stephens” was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/03/14/cutera-cutr-receives-new-coverage-from-analysts-at-stephens.html.
Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.
Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.